Successful Micafungin (FK463) Treatment of Invasive Pulmonary Aspergillosis in a Patient with Acute Lymphoblastic Leukemia in a Phase II Study
- 63 Downloads
We treated a 52-year-old woman with acute lymphoblastic leukemia (ALL) who developed invasive pulmonary aspergillosis (IPA) as a result of neutropenia following remission-induction chemotherapy. Although serological test results, such as those for platelia and pastrex, were all negative and the serum level of β-D—glucan was low,Aspergillus DNA was detected in blood by the polymerase chain reaction method. A clinically documented diagnosis of IPA was made on the basis of chest x-rays, computed tomography scan findings, and the detection ofAspergillus DNA. Micafungin (FK463), a candin class anti-fungal agent, was administered at a dose of 75 to 150 mg/day, because other antifungal agents were not effective. The increase in serum concentration of micafungin was dose-dependent and was accompanied by improvement of symptoms and objective findings. Micafungin was effective for the treatment of IPA in this patient with ALL.
Key wordsInvasive pulmonary aspergillosis Micafungin (FK463) Candin Acute lymphoblastic leukemia Aspergillus DNA
Unable to display preview. Download preview PDF.
- 2.Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.Blood. 1999;93:3654–3661.Google Scholar
- 9.Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.Antimicrob Agents Chemother. 2002;46:1857–1869.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Verweij PE, Stynen D, Rijs AJ, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients.J Clin Microbiol. 1995;33:1912–1914.PubMedPubMedCentralGoogle Scholar
- 16.Azuma J, Nakahara K, Kagayama A, Okuma T, Kawamura A, Mukai T. Pharmacokinetic study of micafungin.J Infect Chemother. 2002;50:155–185.Google Scholar
- 17.Kaneko H, Yamato Y, Hashimoto T, et al. Drug interactions of micafunginin vitro. J Infect Chemother. 2002;50:94–103.Google Scholar